Kahira Pharmaceuticals & Chemical Industries Company (EGX:CPCI)

EGX:CPCI Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	443.72	246.11	97.09	165.74	124.3
Depreciation & Amortization	36.03	5.32	15.94	-	-
Other Amortization	0.01	0.01	0.01	-	-
Other Operating Activities	-101.04	11.45	-24.52	-113.92	37.95
Operating Cash Flow	378.72	262.89	88.53	51.83	162.25
Operating Cash Flow Growth	44.06%	196.96%	70.82%	-68.06%	-
Capital Expenditures	-139.47	-216.24	-79.07	-17.31	-23.68
Sale of Property, Plant & Equipment	-	-	0.08	0	0.04
Investment in Securities	-	-0.84	-	15.86	-14.11
Other Investing Activities	21.12	-14.5	2.85	4.94	2.62
Investing Cash Flow	-118.35	-231.58	-76.14	3.49	-35.13
Long-Term Debt Issued	-	133.88	144.31	-	-
Long-Term Debt Repaid	-36.67	-50.76	-28.36	-	-
Net Debt Issued (Repaid)	-36.67	83.12	115.95	-	-
Common Dividends Paid	-220.78	-85.53	-100.82	-75.2	-77.73
Financing Cash Flow	-257.45	-2.41	15.13	-75.2	-77.73
Net Cash Flow	2.93	28.9	27.51	-19.89	49.39
Free Cash Flow	239.25	46.65	9.45	34.52	138.57
Free Cash Flow Growth	412.87%	393.48%	-72.61%	-75.09%	-
Free Cash Flow Margin	11.51%	3.43%	0.94%	3.10%	13.05%
Free Cash Flow Per Share	16.02	3.12	0.63	2.31	9.28
Cash Interest Paid	-	-	5.85	-	-
Cash Income Tax Paid	93	45.89	73.12	51.33	36.22
Levered Free Cash Flow	146.4	-42.26	57.94	-20.17	97.35
Unlevered Free Cash Flow	154.86	-30.42	60.12	-20.17	97.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.